Vazobral, tablets, 30 pcs.

Combination drug.

a-Dihydroergocriptine is a dihydrogenated derivative of ergot alkaloid, blocks a1- and a2-adrenoreceptors. It has dopaminergic and serotoninergic effects, reduces platelet and erythrocyte aggregation, decreases vascular wall permeability, increases the number of functioning capillaries, improves blood circulation and metabolic processes in the brain, increases resistance of brain tissue to hypoxia.

Pharmacological effect

Combined drug.

a-Dihydroergocriptine is a dihydrogenated derivative of ergot alkaloid, blocks a1- and a2-adrenergic receptors. It has a dopaminergic, serotonergic effect, reduces platelet and erythrocyte aggregation, reduces the permeability of the vascular wall, increases the number of functioning capillaries, improves blood circulation and metabolic processes in the brain, and increases the resistance of brain tissue to hypoxia.

Special instructions

Vasobral has a vasodilating effect without affecting systemic blood pressure.

Active ingredient

Dihydroergocriptine, Caffeine

Composition

1 tablet contains:

active ingredients:

Dihydroergocriptine a-mesylate – 4.0 mg

caffeine – 40.00 mg;

excipients:

lactose monohydrate – 94.1 mg,

microcrystalline cellulose (Avicel PH102) – 60.0 mg,

magnesium stearate – 1.5 mg,

anhydrous colloidal silicon dioxide (Aerosil 200) – 0.4 mg.

Pregnancy

There are no clinical data on the use of Vazobral during pregnancy and lactation.

Use of the drug during breastfeeding may lead to a decrease in lactation.

Contraindications

Increased individual sensitivity to the components of the drug.

Contraindication for long-term use: signs of heart valve defects identified by echocardiography performed before starting the drug.

Side Effects

The incidence of adverse events/adverse reactions (AE/AR) when taking the drug is presented according to the following gradation (World Health Organization classification): very often ≥10%; often ≥1% and <10%; uncommon ≥0.1% and <1%; rarely ≥0.01% and <0.1%; very rare <0.01%.Gastrointestinal disordersNausea (especially when taking the drug on an empty stomach), gastralgia, and dyspepsia are possible; with these manifestations, discontinuation of the drug is not required.Cardiac disordersVery rare: tachycardia, decreased blood pressure, heart defects (including defects with blood regurgitation) and associated conditions (pericarditis, pericardial effusion).Nervous system disorders Rare: dizziness, agitation, headache.Immune system disorders Very rare: allergic reactions.

Interaction

With the simultaneous administration of Vasobral and antihypertensive drugs, an additional decrease in blood pressure is possible.

Overdose

An overdose may cause vomiting.

Storage conditions

At a temperature of 15 – 25 ° C, out of the reach of children

Shelf life

4 years. Do not use after expiration date.

Manufacturer

Chiesi Pharmaceuticals S.p.A., Italy